| Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review |
|
Journal of Women's Health |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| A Survey of Provider Practices for Diagnosis and Treatment of Pediatric Moderate Aplastic Anemia From the North American Pediatric Aplastic Anemia Consortium |
|
Journal of Pediatric Hematology/Oncology (JPHO) |
Aplastic Anemia |
| Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome |
|
Journal of Pediatric Hematology/Oncology |
Aplastic Anemia |
| Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes |
|
Journal of Patient-Reported Outcomes |
Myelodysplastic Syndromes (MDS) |
| Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs |
|
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease |
|
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology |
|
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria |
|
Journal of Managed Care & Specialty Pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes |
|
Journal of Internal Medicine |
Myelodysplastic Syndromes (MDS) |
